Wall Street Breakfast Podcast: Novo Nordisk Trims Outlook On Rising Rivalry

  Listen below or on the go on Apple Podcasts and Spotify    Novo Nordisk (NVO) plans cost cuts amid slower Wegovy growth outlook. (00:22) Disney’s (DIS) ESPN to acquire NFL media assets. (01:35) OpenAI reportedly exploring share sale at $500B valuation. (03:14) This is an abridged transcript. Novo Nordisk (NVO) is cutting costs. The Danish drugmaker says it is facing increasing competition from Eli Lilly (LLY) and generic versions of its obesity drug Wegovy, with slower growth expected for its treatmen ...